ArticleEndocrinology2018
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Article in Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 75 citations in OpenAlex.
- Systems genetics approaches model the heritable architecture of polyendocrine metabolic ovarian syndrome.The Journal of clinical investigation · 2026Article
- GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome.EBioMedicine · 2026Article
- Hyperandrogenism and polycystic ovary syndrome phenotypes in idiopathic intracranial hypertension.Irish journal of medical science · 2026Article
- Exploring the therapeutic potential of Lupeol isolated from Ochrosia elliptica Labill. leaves in polycystic ovarian syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions.Biomedicines · 2026Review
- Curative potential of resveratrol and pterostilbene against epoxy resin-induced reproductive toxicity in female rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ameliorating effect of veratric acid against mercury-induced neurologic deficit and reproductive toxicity in female rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A review on herbal interventions and nanotechnological advancements for managing polycystic ovarian syndrome.JBRA assisted reproduction · 2025Review
- Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in granulosa cells.Journal of ovarian research · 2025Article
- Ovarian epigenetics modifications following lifestyle interventions by exercise and alternate-day feeding in letrozole-induced PCOS rats.Scientific reports · 2025Article
- Differential Effects of Canonical Androgens and 11-Ketotestosterone on Reproductive Phenotypes and Folliculogenesis in Mouse Model of PCOS.Biomedicines · 2025Article
- Article
- Targeted inhibition of kisspeptin neurons reverses hyperandrogenemia and abnormal hyperactive LH secretion in a preclinical mouse model of polycystic ovary syndrome.Human reproduction (Oxford, England) · 2024Article
- Androgens exacerbate hepatic triglyceride accumulation in rats with polycystic ovary syndrome by downregulating MTTP expression.Endocrine · 2024Article
- NLRP3 Inflammasome-dependent Pathway is Involved in the Pathogenesis of Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Age-Dependent Changes in the Effects of Androgens on Female Metabolic and Body Weight Regulation Systems in Humans and Laboratory Animals.International journal of molecular sciences · 2023Review
- Article
- Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.Biology of reproduction · 2023Article
- Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Effects of time-restricted feeding on letrozole-induced mouse model of polycystic ovary syndrome.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women of reproductive age, is characterized by hyperandrogenism, anovulation, and polycystic ovaries. Although its etiology is unknown, excess androgens are thought to be a critical factor driving the pathology of PCOS. We previously demonstrated that continuous exposure to the aromatase inhibitor letrozole (LET) in mice produces many hallmarks of PCOS, including elevated testosterone (T) and luteinizing hormone, anovulation, and obesity. In the current study, we sought to determine whether androgen receptor (AR) actions are responsible for any of the phenotypes observed in LET mice. C57BL/6 female mice were subcutaneously implanted with LET or placebo control and subsequently treated with the nonsteroidal AR antagonist flutamide or vehicle control. Flutamide treatment in LET females reversed elevated T levels and restored ovarian expression of Cyp17a1 (critical for androgen synthesis) to normal levels. Pituitary expression of Lhb was decreased in LET females that received flutamide treatment, with no changes in expression of Fshb or Gnrhr. Flutamide treatment also restored estrous cycling and reduced the number of ovarian cyst-like follicles in LET females. Furthermore, body weight and adipocyte size were decreased in flutamide-treated LET females. Altogether, our findings provide strong evidence that AR signaling is responsible for many key reproductive and metabolic PCOS phenotypes and further establish the LET mouse model as an important tool for the study of androgen excess.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.